Developer docs
API playgroundTry for free, no card

Search company profiles

IDEAYA Biosciences

Full company profile

uuid0000gwj

Namestring
IDEAYA Biosciences
Legal namestring
IDEAYA Biosciences, Inc.
Websiteurl
ideayabio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted therapeutics for molecularly defined solid tumors. Founded in 2015 and headquartered in South San Francisco, IDEAYA applies synthetic lethality, ADC+DDR combinations, MTAP-pathway targeting, and epigenetic inhibition (KAT6/7) to cancers driven by specific genetic alterations. The company has 13 clinical-stage programs across four platform pillars: PKC inhibition (darovasertib for uveal melanoma), ADC+DDR combinations (IDE849 DLL3 ADC, IDE034 B7H3/PTK7 bispecific ADC, IDE161 PARG inhibitor), MTAP-pathway targeting (IDE397 MAT2A inhibitor, IDE892 MTA-cooperative PRMT5 inhibitor), and KAT6/7 dual inhibition (IDE574). Four registrational trials are ongoing for darovasertib in uveal melanoma, with an NDA accepted by the FDA in April 2026 under the RTOR program for first-line HLA-A*02:01-negative metastatic disease and Breakthrough Therapy Designation in the neoadjuvant setting.

The company is pre-commercial and generates no product revenue, with current income sourced from collaboration milestones, license payments, and grants. Q1 2026 collaboration revenue was $10.88M, and the company reported approximately $1.05B in cash plus marketable securities at year-end 2025, augmented by a $345M June 2026 public offering. IDEAYA retains U.S. rights to darovasertib (Servier holds ex-U.S. rights via a $210M upfront deal) and is building a specialty oncology commercial organization led by a newly appointed Chief Commercial Officer targeting a 2027 U.S. launch in HLA-A*02:01-negative metastatic uveal melanoma - a setting with no approved therapies. The company also pursues combination and co-development collaborations with Roche, AstraZeneca, Pfizer, Jiangsu Hengrui, and Biocytogen, while operating global Phase 1/2 trials across North America, Europe, Australia, South America, and Asia.

Short descriptiontext

IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted small molecules and antibody-drug conjugates for genetically defined solid tumors, with a lead registrational asset (darovasertib) in uveal melanoma under FDA review.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, targeted cancer therapies, synthetic lethality drugs, antibody drug conjugates, kinase inhibitor oncology
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Oncology Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Potential future product sales
TypeOne Time License
Description

IDEAYA is pre-commercial and does not yet generate product revenue. The company is advancing darovasertib toward a potential FDA approval and commercial launch in 2027 for metastatic uveal melanoma. Future revenue would derive from product sales in the U.S., subject to regulatory approval.

stocktitan.net
2Milestone payments from Servier (darovasertib ex-U.S.)
TypeLicensing Royalties
Description

IDEAYA received a $210 million upfront payment from Servier under an exclusive ex-U.S. licensing agreement for darovasertib, with up to $320 million in remaining potential regulatory and commercial milestone payments, plus double-digit royalties on ex-U.S. net sales.

fiercebiotech.com
3Partnership and milestone revenue
TypeLicensing Royalties
Description

Additional revenue may come from existing and future partnerships including milestone payments upon achievement of clinical, regulatory, and commercial objectives (e.g., Roche collaboration, Jiangsu Hengrui licensing, Biocytogen milestones).

prnewswire.com
4Q3 2025 collaboration revenue
TypeLicensing Royalties
Description

IDEAYA reported Q3 2025 net income and revenue, partly attributable to the $210 million upfront payment from Servier recognized in prior periods, as well as ongoing collaboration and grant revenue from partnerships.

marketscreener.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IDEAYA Biosciences is a clinical-stage precision medicine oncology company that discovers and develops targeted small molecules and antibody-drug conjugates for patients with molecularly defined solid tumors. Its pipeline spans PKC inhibition (darovasertib) for uveal melanoma, DLL3 and bispecific B7H3/PTK7 ADCs for solid tumors, and synthetic lethality programs (MAT2A, PRMT5, PARG, KAT6/7 inhibitors) for MTAP-deleted and other genetically defined cancers. The company is pre-commercial and preparing for potential FDA approval and 2027 launch of darovasertib in metastatic uveal melanoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Darovasertib + crizotinib achieved 6.9-month median PFS vs 3.1 months for investigator's choice (HR: 0.42, p<0.0001), representing a 58% reduction in risk of disease progression in first-line HLA-A*02:01-negative metastatic uveal melanoma (Phase 2/3 OptimUM-02 trial, n=313 patients)
+4 more records
Product overview1 text field

IDEAYA Biosciences is a precision medicine oncology company with a pipeline of clinical-stage targeted therapies focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. The core pipeline consists of darovasertib (PKC inhibitor for uveal melanoma), IDE849 (DLL3 TOP1 ADC for small cell lung cancer), IDE034 (B7H3/PTK7 bispecific ADC), IDE161 (PARG inhibitor), IDE397 (MAT2A inhibitor), IDE892 (PRMT5 inhibitor), and IDE574 (KAT6/7 dual inhibitor). The company is preparing for commercial launch of darovasertib with NDA under FDA review, while advancing multiple Phase 1 and registrational clinical trials across its ADC+DDR and MTAP pathway programs.

Product and service6 records
1Darovasertib
CategoryPrecision Oncology Therapeutics (Small Molecule Kinase Inhibitor)
Description

A potential first-in-class protein kinase C (PKC) inhibitor targeting the primary oncogenic driver in uveal melanoma. Currently in late-stage registrational trials across all stages of uveal melanoma, with NDA under FDA review for metastatic disease.

2IDE849
CategoryPrecision Oncology Therapeutics (Antibody-Drug Conjugate)
Description

A DLL3-targeting TOP1 antibody-drug conjugate (ADC) for DLL3-expressing tumors including small cell lung cancer and neuroendocrine carcinomas. Phase 1/2 study evaluating monotherapy and combination with durvalumab or IDE161.

3IDE034
CategoryPrecision Oncology Therapeutics (Bispecific Antibody-Drug Conjugate)
Description

A first-in-class B7H3/PTK7 bispecific TOP1 antibody-drug conjugate designed to preferentially target tumor cells co-expressing both proteins. Phase 1 trial for locally advanced/metastatic solid tumors.

4IDE161
CategoryPrecision Oncology Therapeutics (Small Molecule DDR Inhibitor)
Description

An oral PARG (Poly(ADP-ribose) glycohydrolase) inhibitor designed to block DNA repair when combined with TOP1-based ADCs, creating synthetic lethality. Phase 1 study in advanced solid tumors.

5IDE397
CategoryPrecision Oncology Therapeutics (Small Molecule Synthetic Lethality)
Description

A potential first-in-class and best-in-class MAT2A inhibitor for MTAP-deleted solid tumors. Reduces SAM availability to suppress methyltransferase activity in MTAP-deleted cancer cells. Phase 1 study ongoing.

6IDE892
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892 (MTA-cooperative PRMT5 inhibitor) in combination with RG6505 (Roche's Phase 1 pan-RAS inhibitor) in MTAP-deleted pancreatic ductal adenocarcinoma. The collaboration targets the genetic co-alterations of MTAP and KRAS in this indication. IDEAYA sponsors the study while Roche provides RG6505.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

IDEAYA announced a clinical collaboration with AstraZeneca to evaluate IDE849 (DLL3 TOP1 ADC) in combination with AstraZeneca's Imfinzi (durvalumab) for extensive-stage small cell lung cancer. IDEAYA sponsors the global Phase 1 study while AstraZeneca supplies Imfinzi. Enrollment is ongoing across North America, Europe, Australia, South America, and Asia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

IDEAYA entered into an exclusive ex-U.S. licensing agreement with Servier for darovasertib. IDEAYA retains all rights in the U.S. and is eligible to receive a total of $320 million in regulatory and commercial milestones plus double-digit royalties on all ex-U.S. net sales. Servier paid a $210 million upfront payment. The companies jointly conducted the Phase 2/3 OptimUM-02 registrational trial. Servier terminated the collaboration in December 2025 per some reports.

4Jiangsu Hengrui Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

IDEAYA has an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for IDE849, a DLL3 TOP1 ADC. IDEAYA controls worldwide rights outside of Greater China. The Phase 1/2 trial for IDE849 is conducted by Jiangsu Hengrui Pharmaceuticals, which has reached therapeutic dose levels with early signs of efficacy.

ideayabio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

IDEAYA has an option and license agreement with Biocytogen for IDE034, a B7H3/PTK7 bispecific TOP1 ADC. Biocytogen originally developed IDE034 and licensed it to IDEAYA in July 2024. The first patient dosing milestone triggered a $5 million payment to Biocytogen. IDEAYA controls worldwide development and commercialization rights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

IDEAYA has a clinical trial collaboration and drug supply agreement with Pfizer for crizotinib (Pfizer's oral c-MET inhibitor). IDEAYA is evaluating darovasertib in combination with crizotinib in metastatic uveal melanoma. Crizotinib is used as the combination partner in the OptimUM-02 registrational trial.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Nuvalent
TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted therapies for cancer, including kinase inhibitors for specific driver mutations. Similar precision medicine approach and clinical-stage profile to IDEAYA.

TypeDirect peer
Description

Precision medicine oncology company using computational approaches to develop targeted therapies for genetically defined cancers, including programs in PI3K and other precision oncology targets.

TypeBroad incumbent
Description

Computational drug discovery company with a precision oncology pipeline, offering a broader platform play with multiple partnered and internal programs. Less focused on synthetic lethality than IDEAYA but comparable in using computational methods to advance precision oncology drug development.

TypeDirect peer
Description

Precision oncology company developing small molecule therapies targeting RNA-modifying proteins for cancer treatment — comparable as a clinical-stage precision oncology developer with biomarker-driven patient selection.

TypeDirect peer
Description

Clinical-stage biotechnology company developing molecular glue degraders for precision oncology targets, including programs in GSPT1 and other cancer-specific vulnerabilities — similar synthetic lethality and precision oncology profile.

TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality-based therapies, with a lead PRMT5 inhibitor program targeting MTAP-deleted cancers — directly comparable to IDEAYA's MTAP pathway strategy.

TypeDirect peer
Description

Precision oncology company developing allosteric, mutation-targeted therapies for genetically defined cancers — directly comparable in precision oncology drug development approach and clinical-stage profile.

8Theseus Pharmaceuticals
TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted kinase inhibitors for cancer, including programs in resistance mutations — comparable precision oncology approach and clinical-stage profile.

TypeDirect peer
Description

Precision oncology company leveraging synthetic lethality to develop targeted therapies for genomically-defined cancers, including programs in DNA damage response and synthetic lethal targets — closely aligned with IDEAYA's synthetic lethality platform.

TypeDirect peer
Description

Clinical-stage precision oncology company targeting chromatin regulatory systems, including programs in BRG1/BRM and other epigenetic targets — comparable to IDEAYA's KAT6/7 epigenetic program and broader synthetic lethality approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IDEAYA Biosciences

Precision Oncology Therapeuticsideayabio.com

IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted small molecules and antibody-drug conjugates for genetically defined solid tumors, with a lead registrational asset (darovasertib) in uveal melanoma under FDA review.

What IDEAYA Biosciences does

IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted therapeutics for molecularly defined solid tumors. Founded in 2015 and headquartered in South San Francisco, IDEAYA applies synthetic lethality, ADC+DDR combinations, MTAP-pathway targeting, and epigenetic inhibition (KAT6/7) to cancers driven by specific genetic alterations. The company has 13 clinical-stage programs across four platform pillars: PKC inhibition (darovasertib for uveal melanoma), ADC+DDR combinations (IDE849 DLL3 ADC, IDE034 B7H3/PTK7 bispecific ADC, IDE161 PARG inhibitor), MTAP-pathway targeting (IDE397 MAT2A inhibitor, IDE892 MTA-cooperative PRMT5 inhibitor), and KAT6/7 dual inhibition (IDE574). Four registrational trials are ongoing for darovasertib in uveal melanoma, with an NDA accepted by the FDA in April 2026 under the RTOR program for first-line HLA-A*02:01-negative metastatic disease and Breakthrough Therapy Designation in the neoadjuvant setting.

The company is pre-commercial and generates no product revenue, with current income sourced from collaboration milestones, license payments, and grants. Q1 2026 collaboration revenue was $10.88M, and the company reported approximately $1.05B in cash plus marketable securities at year-end 2025, augmented by a $345M June 2026 public offering. IDEAYA retains U.S. rights to darovasertib (Servier holds ex-U.S. rights via a $210M upfront deal) and is building a specialty oncology commercial organization led by a newly appointed Chief Commercial Officer targeting a 2027 U.S. launch in HLA-A*02:01-negative metastatic uveal melanoma - a setting with no approved therapies. The company also pursues combination and co-development collaborations with Roche, AstraZeneca, Pfizer, Jiangsu Hengrui, and Biocytogen, while operating global Phase 1/2 trials across North America, Europe, Australia, South America, and Asia.

IDEAYA Biosciences firmographics

Firmographics
Name
IDEAYA Biosciences
Legal name
IDEAYA Biosciences, Inc.
Website
https://ideayabio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted small molecules and antibody-drug conjugates for genetically defined solid tumors, with a lead registrational asset (darovasertib) in uveal melanoma under FDA review.
Ownership category
akta.pro rank

IDEAYA Biosciences industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Targeted cancer therapies
  • Synthetic lethality drugs
  • Antibody drug conjugates
  • Kinase inhibitor oncology

Where IDEAYA Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IDEAYA Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Potential future product sales: IDEAYA is pre-commercial and does not yet generate product revenue. The company is advancing darovasertib toward a potential FDA approval and commercial launch in 2027 for metastatic uveal melanoma. Future revenue would derive from product sales in the U.S., subject to regulatory approval.
  2. Milestone payments from Servier (darovasertib ex-U.S.): IDEAYA received a $210 million upfront payment from Servier under an exclusive ex-U.S. licensing agreement for darovasertib, with up to $320 million in remaining potential regulatory and commercial milestone payments, plus double-digit royalties on ex-U.S. net sales.
  3. Partnership and milestone revenue: Additional revenue may come from existing and future partnerships including milestone payments upon achievement of clinical, regulatory, and commercial objectives (e.g., Roche collaboration, Jiangsu Hengrui licensing, Biocytogen milestones).
  4. Q3 2025 collaboration revenue: IDEAYA reported Q3 2025 net income and revenue, partly attributable to the $210 million upfront payment from Servier recognized in prior periods, as well as ongoing collaboration and grant revenue from partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

IDEAYA Biosciences product offering

Product offering

Core offering

IDEAYA Biosciences is a clinical-stage precision medicine oncology company that discovers and develops targeted small molecules and antibody-drug conjugates for patients with molecularly defined solid tumors. Its pipeline spans PKC inhibition (darovasertib) for uveal melanoma, DLL3 and bispecific B7H3/PTK7 ADCs for solid tumors, and synthetic lethality programs (MAT2A, PRMT5, PARG, KAT6/7 inhibitors) for MTAP-deleted and other genetically defined cancers. The company is pre-commercial and preparing for potential FDA approval and 2027 launch of darovasertib in metastatic uveal melanoma.

Product overview

IDEAYA Biosciences is a precision medicine oncology company with a pipeline of clinical-stage targeted therapies focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. The core pipeline consists of darovasertib (PKC inhibitor for uveal melanoma), IDE849 (DLL3 TOP1 ADC for small cell lung cancer), IDE034 (B7H3/PTK7 bispecific ADC), IDE161 (PARG inhibitor), IDE397 (MAT2A inhibitor), IDE892 (PRMT5 inhibitor), and IDE574 (KAT6/7 dual inhibitor). The company is preparing for commercial launch of darovasertib with NDA under FDA review, while advancing multiple Phase 1 and registrational clinical trials across its ADC+DDR and MTAP pathway programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Darovasertib A potential first-in-class protein kinase C (PKC) inhibitor targeting the primary oncogenic driver in uveal melanoma. Currently in late-stage registrational trials across all stages of uveal melanoma, with NDA under FDA review for metastatic disease.
  • IDE849 A DLL3-targeting TOP1 antibody-drug conjugate (ADC) for DLL3-expressing tumors including small cell lung cancer and neuroendocrine carcinomas. Phase 1/2 study evaluating monotherapy and combination with durvalumab or IDE161.
  • IDE034 A first-in-class B7H3/PTK7 bispecific TOP1 antibody-drug conjugate designed to preferentially target tumor cells co-expressing both proteins. Phase 1 trial for locally advanced/metastatic solid tumors.
  • IDE161 An oral PARG (Poly(ADP-ribose) glycohydrolase) inhibitor designed to block DNA repair when combined with TOP1-based ADCs, creating synthetic lethality. Phase 1 study in advanced solid tumors.
  • IDE397 A potential first-in-class and best-in-class MAT2A inhibitor for MTAP-deleted solid tumors. Reduces SAM availability to suppress methyltransferase activity in MTAP-deleted cancer cells. Phase 1 study ongoing.
  • IDE892

Quantifiable outcome

  • Darovasertib + crizotinib achieved 6.9-month median PFS vs 3.1 months for investigator's choice (HR: 0.42, p<0.0001), representing a 58% reduction in risk of disease progression in first-line HLA-A*02:01-negative metastatic uveal melanoma (Phase 2/3 OptimUM-02 trial, n=313 patients)
  • +4 more outcomes

Companies that use IDEAYA Biosciences

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

IDEAYA Biosciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

IDEAYA Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • RochecoreStrategic or Co-development Partner · 3 June 2026IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892 (MTA-cooperative PRMT5 inhibitor) in combination with RG6505 (Roche's Phase 1 pan-RAS inhibitor) in MTAP-deleted pancreatic ductal adenocarcinoma. The collaboration targets the genetic co-alterations of MTAP and KRAS in this indication. IDEAYA sponsors the study while Roche provides RG6505.
  • AstraZenecaminorStrategic or Co-development Partner · 9 April 2026IDEAYA announced a clinical collaboration with AstraZeneca to evaluate IDE849 (DLL3 TOP1 ADC) in combination with AstraZeneca's Imfinzi (durvalumab) for extensive-stage small cell lung cancer. IDEAYA sponsors the global Phase 1 study while AstraZeneca supplies Imfinzi. Enrollment is ongoing across North America, Europe, Australia, South America, and Asia.
  • ServiercoreStrategic or Co-development Partner · 1 January 2025IDEAYA entered into an exclusive ex-U.S. licensing agreement with Servier for darovasertib. IDEAYA retains all rights in the U.S. and is eligible to receive a total of $320 million in regulatory and commercial milestones plus double-digit royalties on all ex-U.S. net sales. Servier paid a $210 million upfront payment. The companies jointly conducted the Phase 2/3 OptimUM-02 registrational trial. Servier terminated the collaboration in December 2025 per some reports.
  • Jiangsu Hengrui PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2025IDEAYA has an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for IDE849, a DLL3 TOP1 ADC. IDEAYA controls worldwide rights outside of Greater China. The Phase 1/2 trial for IDE849 is conducted by Jiangsu Hengrui Pharmaceuticals, which has reached therapeutic dose levels with early signs of efficacy.
  • BiocytogencoreStrategic or Co-development Partner · 1 July 2024IDEAYA has an option and license agreement with Biocytogen for IDE034, a B7H3/PTK7 bispecific TOP1 ADC. Biocytogen originally developed IDE034 and licensed it to IDEAYA in July 2024. The first patient dosing milestone triggered a $5 million payment to Biocytogen. IDEAYA controls worldwide development and commercialization rights.
  • PfizercoreStrategic or Co-development Partner · 1 January 2019IDEAYA has a clinical trial collaboration and drug supply agreement with Pfizer for crizotinib (Pfizer's oral c-MET inhibitor). IDEAYA is evaluating darovasertib in combination with crizotinib in metastatic uveal melanoma. Crizotinib is used as the combination partner in the OptimUM-02 registrational trial.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

IDEAYA Biosciences competitors and assessment

Company assessment

Direct peers

  • Nuvalent: Clinical-stage precision oncology company developing targeted therapies for cancer, including kinase inhibitors for specific driver mutations. Similar precision medicine approach and clinical-stage profile to IDEAYA.
  • Relay Therapeutics: Precision medicine oncology company using computational approaches to develop targeted therapies for genetically defined cancers, including programs in PI3K and other precision oncology targets.
  • Accent Therapeutics: Precision oncology company developing small molecule therapies targeting RNA-modifying proteins for cancer treatment — comparable as a clinical-stage precision oncology developer with biomarker-driven patient selection.
  • Monte Rosa Therapeutics: Clinical-stage biotechnology company developing molecular glue degraders for precision oncology targets, including programs in GSPT1 and other cancer-specific vulnerabilities — similar synthetic lethality and precision oncology profile.
  • Tango Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies, with a lead PRMT5 inhibitor program targeting MTAP-deleted cancers — directly comparable to IDEAYA's MTAP pathway strategy.
  • Black Diamond Therapeutics: Precision oncology company developing allosteric, mutation-targeted therapies for genetically defined cancers — directly comparable in precision oncology drug development approach and clinical-stage profile.
  • Theseus Pharmaceuticals: Clinical-stage precision oncology company developing targeted kinase inhibitors for cancer, including programs in resistance mutations — comparable precision oncology approach and clinical-stage profile.
  • Repare Therapeutics: Precision oncology company leveraging synthetic lethality to develop targeted therapies for genomically-defined cancers, including programs in DNA damage response and synthetic lethal targets — closely aligned with IDEAYA's synthetic lethality platform.
  • Foghorn Therapeutics: Clinical-stage precision oncology company targeting chromatin regulatory systems, including programs in BRG1/BRM and other epigenetic targets — comparable to IDEAYA's KAT6/7 epigenetic program and broader synthetic lethality approach.

Broad incumbents

  • Schrödinger: Computational drug discovery company with a precision oncology pipeline, offering a broader platform play with multiple partnered and internal programs. Less focused on synthetic lethality than IDEAYA but comparable in using computational methods to advance precision oncology drug development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

IDEAYA Biosciences social profiles

Digital presence

IDEAYA Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IDEAYA Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

IDEAYA Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IDEAYA Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDEAYA Biosciences

What does IDEAYA Biosciences do?

IDEAYA Biosciences is a clinical-stage precision medicine oncology company that discovers and develops targeted small molecules and antibody-drug conjugates for patients with molecularly defined solid tumors. Its pipeline spans PKC inhibition (darovasertib) for uveal melanoma, DLL3 and bispecific B7H3/PTK7 ADCs for solid tumors, and synthetic lethality programs (MAT2A, PRMT5, PARG, KAT6/7 inhibitors) for MTAP-deleted and other genetically defined cancers. The company is pre-commercial and preparing for potential FDA approval and 2027 launch of darovasertib in metastatic uveal melanoma.

Is IDEAYA Biosciences a public or private company?

IDEAYA Biosciences is a public company. It is classified as public and is currently operating.

When was IDEAYA Biosciences founded?

IDEAYA Biosciences was founded in 2015. It employs 101 to 250 people.

Where is IDEAYA Biosciences based?

IDEAYA Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does IDEAYA Biosciences make money?

Four revenue lines are on record. Potential future product sales are the primary driver. The others are milestone payments from Servier (darovasertib ex-U.S.), partnership and milestone revenue and Q3 2025 collaboration revenue.

Who are IDEAYA Biosciences's main competitors?

Direct peers on record are Nuvalent, Relay Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Tango Therapeutics, Black Diamond Therapeutics, Theseus Pharmaceuticals, Repare Therapeutics and Foghorn Therapeutics. Schrödinger is listed as a broad incumbent.

Does IDEAYA Biosciences have an API?

No public API is recorded for IDEAYA Biosciences.

What industry is IDEAYA Biosciences in?

IDEAYA Biosciences's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldIDEAYA Biosciences, Inc. $IDYA Shares Bought by Aberdeen Group plcAberdeen Group raised its IDEAYA Biosciences stake by 5.3% in Q3, holding 590,777 shares. IDEAYA reported Q3 EPS of -$1.22, missing estimates, but revenue rose 14.6% to $10.24 million. Analysts rate the stock a Moderate Buy with an average price target of $49.55.YahooIs IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?IDEAYA Biosciences outlined an FDA-backed registrational plan for IDE849, but its share price fell 16.56% over 30 days. Analysts see fair value at $52.75, implying the stock is undervalued, though execution risks remain.Seeking AlphaIdeaya Biosciences: Staying Bullish On Darovasertib NDA Submission And MoreIDEAYA Biosciences completed its NDA submission for darovasertib plus crizotinib for metastatic uveal melanoma in Q3 2026. The company also reported positive phase 1 data for its DLL3-targeting ADC IDE849, with a 36.8% confirmed ORR in NEC patients, and gained FDA alignment for a single-arm extension cohort to seek accelerated approval for GEP-NEC.TradingViewRBC Capital maintains IDEAYA Biosciences at Outperform, keeps price target at $45RBC Capital maintained IDEAYA Biosciences at Outperform with a price target of $45, implying 48.2% upside from the Nov 16 close of $30.36. The target is among five recent analyst price targets ranging from $39 to $66.Seeking AlphaIDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 TranscriptIDEAYA Biosciences CEO Yujiro Hata presented at the UBS Global Biopharma Conference, stating the company filed its first NDA and reported top-line results at ASCO. The lead drug darovasertib for metastatic uveal melanoma may receive potential approval in 2027, with a broader pipeline also discussed.Seeking AlphaIdeaya picks cancer drug candidate, targets human trial application in 2027Ideaya Biosciences selected IDE101 as a drug candidate to treat cancers lacking CDKN2A, a gene that normally prevents uncontrolled cell growth. The company plans to seek U.S. regulatory permission to begin human testing, targeting a 2027 application.TradingViewIdeaya picks cancer drug candidate, targets human trial application in 2027Ideaya Biosciences selected IDE101 as a drug candidate for cancers lacking CDKN2A, targeting U.S. regulatory approval for human trials in the first half of 2027. The preclinical candidate blocks two cyclin-dependent kinases, with loss of CDKN2A occurring in 10-15% of solid tumors and 70% of pancreatic ductal adenocarcinomas.PRESSBEEIDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors ...Middle EastIDEAYA Biosciences announced the nomination of IDE101 as a development candidate, a potential first-in-class inhibitor targeting CDKN2A-deficiency in solid tumors. The candidate showed encouraging preclinical activity in CDKN2A-deficient tumor models as a monotherapy and in combination with RAS and MTAP inhibitors, including IDEAYA's Phase 1 PRMT5 inhibitor IDE892.The future of tradingIDEAYA Biosciences Names IDE101 Development Candidate for CDKN2A-Deficient Solid TumorsIDEAYA Biosciences nominated IDE101 as a development candidate for CDKN2A-deficient solid tumors, with an FDA investigational new drug filing planned for first-half 2027. Preclinical studies showed activity alone and with RAS or PRMT5 inhibitors, including IDE892. Results will be presented at the company's London R&D Day.Simply Wall StIDEAYA Biosciences (IDYA) Stock May Be Pricey Despite Uveal Melanoma Drug ProgressIDEAYA Biosciences has gained 35.6% over five years, with its uveal melanoma drug application and Phase 3 plans driving optimism. The stock trades at a P/B of 2.8x, above the biotech sector average of 1.8x but below specialist peers near 7.3x. Further upside depends on how clinical milestones add value to the book.